-

05:49:28 PM

LIVE Real Time LLY Stock Market News

LLY - Lilly(Eli) & Co

05/06/21 6:45 AM

NYSE : LLY

Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes

With a goal of integrating data and technology to help streamline diabetes management, Eli Lilly and Company (NYSE: LLY) signed strategic international agreements with four companies - DexCom, Inc., Glooko Inc., myDiabby Healthcare and Roche - to advance

RHEA-AI

neutral

05/05/21 10:00 AM

NYSE : LLY

Lilly to Participate in Bank of America Securities 2021 Health Care Conference

Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2021 Health Care Conference on Tuesday, May 11, 2021. Michael Mason, senior vice president, president of Lilly Diabetes, will participate in a virtual fireside chat at 9:30

RHEA-AI

neutral

05/04/21 10:07 AM

NYSE : LLY

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries

Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. This donation

RHEA-AI

neutral

05/04/21 7:00 AM

NYSE : LLY

Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe

Eli Lilly and Company (NYSE: LLY) will outline its newly updated Environmental, Social and Governance (ESG) strategy, highlighting its commitments in key areas during the company's Sustainability Webcast today at 10:30 am ET. In addition, Lilly has launched

RHEA-AI

positive

05/04/21 6:42 AM

NYSE : LLY

Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements

Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Lilly is offering

RHEA-AI

negative

05/03/21 3:28 PM

NYSE : LLY

Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization

The board of directors of Eli Lilly and Company (NYSE: LLY) (the "Board") has declared a dividend for the second quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable on June 10, 2021 to shareholders of record at the close

RHEA-AI

neutral

05/03/21 10:00 AM

NYSE : LLY

Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity

Eli Lilly and Company (NYSE: LLY) today announced its support of Direct Relief's Fund for Health Equity (the Fund) with a $5 million commitment over the next five years. The Fund launched in March 2020 with $75 million raised against a goal of $150

RHEA-AI

neutral

04/27/21 6:25 AM

NYSE : LLY

Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance

Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2021.$ in millions, except per share dataFirst Quarter%20212020ChangeRevenue$6,805.6$5,859.816%Net Income - Reported1,355.31,456.5(7)%EPS -

RHEA-AI

neutral

04/23/21 10:01 AM

Nasdaq, NYSE : INCY, LLY

OLUMIANT(R) Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses

Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and Incyte's (NASDAQ:INCY) OLUMIANT (R) (baricitinib) 2-mg tablet taken once daily showed improvement

RHEA-AI

neutral

04/23/21 10:01 AM

NYSE : LLY

Taltz(R) Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis

Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's (NYSE: LLY) Taltz (R) (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next